{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"due to low accrual rates, no analyses was done to compare the new combination of Velcade/Melphalan/Dexamethasone vs. Velcade/Thalidomide/Dexamethasone","groups":[{"description":"Velcade 1.0 mg/m\\^2 Velcade 1.3 mg/m\\^2 D1,4, 8, 11 (x 6 cycles, then 1.0 mg/m\\^2 (for cycles 7-12) Thalidomide 100 mg D1-28 Dexamethasone 20 mg D1-4 and 8-11","id":"OG000","title":"Velcade, Thalidomide, and Dexamethasone"},{"description":"VMD:\n\nVelcade 1.3 mg/m\\^2 D1, 4, 7, 10 (x6 mo, then 1.0 mg/m\\^2) Melphalan 4 (6, 8, 10) mg/m\\^2 D1, 4, 7, 10 dose escalation Dexamethasone 20 mg 1-4 and 7-10","id":"OG001","title":"VMD With Melphalan Dose Escalation"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Participant Survival With Velcade/Melphalan/Dexamethasone Treatment vs. Participant Survival With Velcade/Thalidomide/Dexamethasone Treatment","type":"PRIMARY","unitOfMeasure":"Participant"}